ABT-199 (Venetoclax) is a specific BCL-2 inhibitor and is FDA-approved for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.